# Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

> **NCT02156466** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 41 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** MSB0010841
- **DRUG:** MSB0010841
- **DRUG:** MSB0010841
- **DRUG:** MSB0010841
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02156466
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156466, "Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02156466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*